TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05455619: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Sponsor: SynDevRx, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 52 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,727,880

Rescue Site Savings

+$1,138,830

Unlock Full NCT05455619 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05455619 Rescue Dossier →